Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Schiller, Michaela; Tsianakas, A; Sterry, Wolfram; Dummer, Reinhard; Hinke, A; Nashan, Dorothee; Stadler, R (2017). Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphom. Journal of the European Academy of Dermatology and Venerology, 31(11):1841-1847.

Whittaker, S; Ortiz, P; Dummer, R; Ranki, A; Hasan, B; Meulemans, B; Gellrich, S; Knobler, R; Stadler, R; Karrasch, M (2012). Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). British Journal of Dermatology, 167(3):678-687.

Pras, A; Schönwälder, J; Burgess, M; Festor, O; Perez, G M; Stadler, R; Stiller, B (2008). Key research challenges in network management. IEEE Communications Magazine, 45(10):104-110.

Garbe, C; Radny, P; Linse, R; Dummer, R; Gutzmer, R; Ulrich, J; Stadler, R; Weichenthal, M; Eigentler, T K; Ellwanger, U; Hauschild, A (2008). Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Annals of Oncology, 19(6):1195-1201.

Stadler, R; Assaf, C; Klemke, C D; Nashan, D; Weichenthal, M; Dummer, R; Sterry, W (2008). Short German guidelines: cutaneous lymphomas. Journal der Deutschen Dermatologischen Gesellschaft, 6(Suppl):S25-S31.

This list was generated on Tue Apr 23 02:02:03 2019 CEST.